Secondary NAD(+) deficiency in the inherited defect of glutamine synthetase by Hu, Liyan et al.








Secondary NAD(+) deficiency in the inherited defect of glutamine
synthetase
Hu, Liyan ; Ibrahim, Khalid ; Stucki, Martin ; Frapolli, Michele ; Shahbeck, Noora ; Chaudhry, Farrukh
A ; Görg, Boris ; Häussinger, Dieter ; Penberthy, W Todd ; Ben-Omran, Tawfeg ; Häberle, Johannes
Abstract: Glutamine synthetase (GS) deficiency is an ultra-rare inborn error of amino acid metabolism
that has been described in only three patients so far. The disease is characterized by neonatal onset
of severe encephalopathy, low levels of glutamine in blood and cerebrospinal fluid, chronic moderate
hyperammonemia, and an overall poor prognosis in the absence of an effective treatment. Recently,
enteral glutamine supplementation was shown to be a safe and effective therapy for this disease but there
are no data available on the long-term effects of this intervention. The amino acid glutamine, severely
lacking in this disorder, is central to many metabolic pathways in the human organism and is involved
in the synthesis of nicotinamide adenine dinucleotide (NAD(+)) starting from tryptophan or niacin as
nicotinate, but not nicotinamide. Using fibroblasts, leukocytes, and immortalized peripheral blood stem
cells (PBSC) from a patient carrying a GLUL gene point mutation associated with impaired GS activity,
we tested whether glutamine deficiency in this patient results in NAD(+) depletion and whether it can
be rescued by supplementation with glutamine, nicotinamide or nicotinate. The present study shows
that congenital GS deficiency is associated with NAD(+) depletion in fibroblasts, leukocytes and PBSC,
which may contribute to the severe clinical phenotype of the disease. Furthermore, it shows that NAD(+)
depletion can be rescued by nicotinamide supplementation in fibroblasts and leukocytes, which may open
up potential therapeutic options for the treatment of this disorder.
DOI: https://doi.org/10.1007/s10545-015-9846-4





Hu, Liyan; Ibrahim, Khalid; Stucki, Martin; Frapolli, Michele; Shahbeck, Noora; Chaudhry, Farrukh A;
Görg, Boris; Häussinger, Dieter; Penberthy, W Todd; Ben-Omran, Tawfeg; Häberle, Johannes (2015).




Secondary NAD+ deficiency in the inherited defect
of glutamine synthetase
Liyan Hu1,2 & Khalid Ibrahim3 & Martin Stucki1 & Michele Frapolli1 & Noora Shahbeck4 &
Farrukh A. Chaudhry5 & Boris Görg6 & Dieter Häussinger6 & W. Todd Penberthy7 &
Tawfeg Ben-Omran4,8,9 & Johannes Häberle1,2
Received: 27 January 2015 /Revised: 3 March 2015 /Accepted: 20 March 2015 /Published online: 21 April 2015
# SSIEM 2015
Abstract Glutamine synthetase (GS) deficiency is an ultra-rare
inborn error of amino acid metabolism that has been described
in only three patients so far. The disease is characterized by
neonatal onset of severe encephalopathy, low levels of gluta-
mine in blood and cerebrospinal fluid, chronic moderate
hyperammonemia, and an overall poor prognosis in the absence
of an effective treatment. Recently, enteral glutamine supple-
mentation was shown to be a safe and effective therapy for this
disease but there are no data available on the long-term effects of
this intervention. The amino acid glutamine, severely lacking in
this disorder, is central to many metabolic pathways in the hu-
man organism and is involved in the synthesis of nicotinamide
adenine dinucleotide (NAD+) starting from tryptophan or niacin
as nicotinate, but not nicotinamide. Using fibroblasts, leuko-
cytes, and immortalized peripheral blood stem cells (PBSC)
from a patient carrying a GLUL gene point mutation associated
with impaired GS activity, we tested whether glutamine defi-
ciency in this patient results in NAD+ depletion and whether it
can be rescued by supplementation with glutamine, nicotin-
amide or nicotinate. The present study shows that congenital
GS deficiency is associated with NAD+ depletion in fibroblasts,
leukocytes and PBSC, which may contribute to the severe clin-
ical phenotype of the disease. Furthermore, it shows that NAD+
depletion can be rescued by nicotinamide supplementation in
fibroblasts and leukocytes, which may open up potential thera-
peutic options for the treatment of this disorder.
Abbreviations
GS Glutamine synthetase
NAD+ Nicotinamide adenine dinucleotide
PBSC Peripheral blood stem cells
Introduction
Glutamine is an abundant, non-essential amino acid and is
central for a wide range of metabolic reactions in all mamma-
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lian organisms (Häussinger 1998). The main functions of glu-
tamine include storage and transport of nitrogen between dif-
ferent organs during fetal development as well as later in life.
The liver, together with skeletal muscle, is the central organ
for maintaining glutamine homeostasis by removing or releas-
ing glutamine from or into the circulation, respectively, as
required. In the central nervous system, astroglial cells are
responsible for maintaining glutamine homeostasis in the ce-
rebrospinal fluid (Chaudhry et al 1999). Glutamine is synthe-
sized in the human body solely by the reaction of glutamine
synthetase (GS; synonymous: glutamate-ammonia ligase; EC
6.3.1.2), a key enzyme in nitrogen metabolism, requiring glu-
tamate, ammonia, and ATP (Farrow et al 1990; Häussinger
1990, 1998). The rate of glutamine synthesis depends on sub-
strate availability, and the expression level and activity of GS
(Häberle et al 2006a). L-glutamine, not D-glutamine, is the
only substrate of the γ-glutamyl transfer reaction of GS (Wu
1977).
GS is predominantly expressed in brain, kidney, muscle,
and liver (Häussinger and Sies 1984; He et al 2010; Krajewski
et al 2008; Liaw et al 1995). In humans, several studies into
the role of GS have focused on the brain (Derouiche and Ohm
1994; Tumani et al 1995; Yamamoto et al 1987) to better
understand various conditions including epilepsy (Eid et al
2004), schizophrenia, Parkinson’s disease (Carlsson and
Carlsson 1990), Huntington’s chorea (Young et al 1988),
Alzheimer’s disease (Hardy and Cowburn 1987) and hepatic
encephalopathy (Häussinger et al 1994). GS is effectively and
irreversibly inhibited by methionine sulfoximine (Abramson
et al 1991).
Inherited GS deficiency (MIM #610015) due to a defect in
the GLUL gene (MIM *138290) is an ultra-rare disorder de-
scribed in only three patients who all suffered from neonatal
onset severe epileptic encephalopathy. The pathophysiology
of GS deficiency is thought to be related to the indispensable
role of GS as the only enzyme for glutamine synthesis in
particular since glutamine is the unique amino moiety donor
for many essential metabolites including purines and pyrimi-
dines, amino acids, glucose precursors, adenosine
monophosphate, and nicotinamide adenine dinucleotide
(NAD+) (Häberle et al 2006b). Treatment of GS deficiency
was suggested with regular enteral glutamine supplementation
but this concept could only be tested in a single patient so far
(Häberle et al 2012).
Nicotinic acid, nicotinamide, or nicotinamide riboside are
the precursors for generation of NAD+ (Fig. 1). These are
collectively and colloquially referred to as niacin or vitamin
B3. The unphosphorylated and phosphorylated forms, NAD+/
NADH and NADP/NADPH, respectively, are essential for
numerous oxido-reduction reactions in the cell (Bieganowski
et al 2003). The transfer of electrons fromNADH to oxygen is
essential for adenosine triphosphate (ATP) formation in aero-
bic metabolism. NAD+ can modulate several cellular
functions such as sensitivity of cells to apoptosis (Luo et al
2001), but the mechanisms regulating cellular NAD+ through
metabolic events remain to be fully elucidated. In humans,
NAD+ is synthesized from deamino-NAD+, ATP, and an ami-
no group from glutamine, a reaction catalyzed by NAD+ syn-
thetase (Fig. 1). In addition to the glutamine-dependent NAD+
synthetase in mammalian cells, there exists an ammonia-
dependent NAD+ synthetase in prokaryotes with different am-
ide donor specificity and tissue distributions (Hara et al 2003;
Spencer and Preiss 1967).
Previously, we had reported on the only living of hitherto
three known GS deficient patients who suffered from chronic
moderate hyperammonemia and severe neonatal–onset en-
cephalopathy (Häberle et al 2011). In this study, we test the
hypothesis that systemic glutamine deficiency impairs NAD+
synthesis, and that NAD+ deficiency can be rescued by sup-
plementation with nicotinamide or nicotinic acid. We there-
fore studied NAD+ levels in different cell lines derived from
the only living GS deficient patient, and indeed found NAD+
deficiency. To our knowledge, this is the first description of
NAD+ deficiency in a patient with systemic glutamine defi-
ciency caused by a mutation in the GLUL gene. Given the
importance of NAD+, the severe phenotype in GS deficiency
Fig. 1 Biochemical pathways involved in the synthesis of NAD+.
Scheme of NAD+ synthesis from deamino-NAD+ requiring the amino
group from glutamine. Included are also alternative routes for NAD+
generation starting from nicotinate, nicotinamide, nicotinamide riboside,
or tryptophan. Respective genes are denoted in italic. Abbreviations: Gln
glutamine, Glu glutamate; IDO indolamin-2,3-dioxygenase, NA
nicotinate/niacinate/nicotinic acid, NaAD nicotinic acid adenine
dinucleotide, NAD nicotinamide adenine dinucleotide, NADS NAD
synthetase, NAM nicotinamide, NaMN nicotinic acid mononucleotide,
NAMPT1 nicotinamide phosphoribosyltransferase (synonymous to
Visfatin or PBEF1, pre-B-cell colony-enhancing factor 1), NAMR
nicotinamide riboside, NMN nicotinamide mononucleotide,
NMNAT1,2,3 nicotinamide mononucleotide adenylyltransferase 1,2,3,
NPT1 nicotinate phosphoribosyltransferase, NRK1,2 Nicotinamide
Riboside Kinase 1,2, PARPs poly (ADP-ribose) polymerase family, Trp
tryptophan, QA quinolinic acid
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may well be caused by the combined deficiencies of gluta-
mine and of NAD+. This finding adds to our understanding of
the pathophysiology of GS deficiency and supports that nico-
tinamide supplementation may be beneficial for treating
NAD+ deficiency in this particular disorder.
Material and methods
Culture of fibroblasts
Patient and control (n=3) fibroblasts were cultured in T75
flasks containing 8 ml of standard DMEM containing 4 mM
GlutaMAX (Invitrogen, Basel, Switzerland), 10 % FBS (PAA
Laboratories, GE Healthcare, Glattbrugg, Switzerland) and
antibiotic-antimycotic (Forget et al 1999). Forty eight hours
prior to cell harvest, the medium was aspirated and cells were
washed with DPBS (Invitrogen). Then, cells were grown for
48 h in 8 ml of above medium without glutamine or supple-
mented with 10 mM GlutaMAX (Gln) (Invitrogen), 1 mM
nicotinamide (NAmide) (Sigma-Aldrich, Buchs, Switzer-
land), 1 mM nicotinic acid (anionic form: nicotinate) (NAte)
(Sigma-Aldrich) or with a combination of 10 mM glutamine
and 1 mM nicotinamide.
Fibroblast harvest and cell count
Fibroblasts were washed with PBS and trypsinized for 10 min
at 37 °C with 1 ml 0.25 % trypsin (Invitrogen) before 4 ml
DMEM was added to the cells. Suspension of cells was kept
as aliquots of 800 μl in Eppendorf tubes. After centrifugation
for five min at 500 g, the supernatant was discarded and pel-
lets, immediately frozen in liquid nitrogen, were stored at -
80 °C until NAD+measurement. To count viable cell numbers
using an improved Neubauer chamber (Brand GmbH,
Wertheim, Germany), another 100 μl of the cell suspension
was mixed with 100 μl of trypan blue (Sigma-Aldrich).
Leukocytes harvest and cell count
To study the safety and efficacy of glutamine supplementa-
tion, a GS deficient patient was treated for 4 weeks with L-
glutamine (doses increasing to a maximum of 1020 mg/kg
bodyweight/day) (Häberle et al 2012). Before treatment and
after the maximum dose of glutamine was achieved, 10 ml of
heparin blood and 1 ml of EDTA blood were collected from
the patient and from untreated controls (n=3). Leukocytes
were counted in EDTA blood by using an automated
haematology analyzer (Sysmex AG, Horgen, Switzerland).
Heparin blood was used to extract leukocytes. For this, red
blood cells were lysed in 30 ml lysis buffer (10 mM KHCO3
and 155 mM NH4Cl) for 15 min prior to centrifugation at
500 g for 5 min. Washing of the leukocyte pellet was done
with decreasing concentrations of NaCl (0.68, 0.34, and
0.17 %) and centrifugation at 850 g for 5 min that was repeat-
ed three times. Cells in 0.17 % NaCl solution were aliquoted
to 6 million leukocytes per vial following the centrifugation
for 5 min at 500 g, the supernatant discarded and pellets im-
mediately frozen in liquid nitrogen until NAD+ measurement.
Transformation of B-lymphocytes to establish peripheral
blood stem cells (PBSC)
Peripheral blood B-cells were transformed using wild-type
EBV B95.8 as described earlier (Dorner et al 2008). Briefly,
peripheral blood mononuclear cells (PBMC) from the patient,
his father and from three controls were isolated by Ficoll gra-
dient centrifugation. Nucleated red blood cells in the patient
sample were lysed using lysis buffer (10 mM KHCO3 and
155 mMNH4Cl) for 15 min. Unseparated PBMCwere infect-
ed with supernatant from a 4-day culture of EBV B95.8 by
conventional inoculation. Cells were cultured in 96-well
plates containing RPMI 1640 (Invitrogen) with 10 % FBS
(PAA), antibiotic-antimycotic (PAA) and 2 mM GlutaMAX
(Invitrogen). One half of the RPMI 1640 medium was
changed every 3 days for 4 weeks.
Growth of peripheral blood stem cells
Peripheral blood stem cells (PBSC) were cultured in upright
T25 flasks containing 20 ml RPMI 1640 (Invitrogen) contain-
ing 10% FBS (PAA), antibiotic-antimycotic (PAA) and 2mM
GlutaMAX (Invitrogen) up to a cell density of at least 300,000
cells per ml. Aggregated cells were dissociated twice weekly
by gentle trituration with a pipette. To split cells or to change
medium, cells were centrifuged for 5 min at 100 g and resus-
pended in fresh medium. For glutamine and nicotinamide ex-
periments, cells were grown in the same medium but without
or with GlutaMAX (10 mM) or 1 mM nicotinamide for 72 h.
To count cells, these were dissociated and 100 μl of the cell
suspension was mixed with 100 μl of trypan blue (Sigma-
Aldrich) and counted using an improved Neubauer chamber
(Brand). The cell solution was aliquoted in order to get 6
million PBSC per vial. These vials were then centrifuged for
5 min at 500 g, the supernatant discarded and the pellets im-
mediately frozen in liquid nitrogen until NAD+ measurement.
Protein extraction and Western blot analysis
Fibroblasts derived from patient and controls were treated
with or without 10 mM glutamine and/or 1 mM nicotinamide
for 2 or 3 days. Media were changed daily. Cells were har-
vested and lysed in complete Nonidet P-40 (Roche Applied
Science, Rotkreuz, Switzerland) lysis buffer containing 1 %
Nonidet P-40, 50 mMTris–HCl (pH 8), 125 mMNaCl, 1 mM
EDTA, and protease inhibitors (1x Complete EDTA-free+
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1 mM of PMSF) (Roche Applied Science). Cell lysates were
then centrifuged at 4 °C for 15 min at 27,000 g. Protein con-
centrations were determined by the method of Lowry (Lowry
et al 1951) using bovine serum albumin (BSA) as standard.
Western blotting was performed as described previously
(Laemmli 1970). A total of 135 μg protein (except for exper-
iments shown in Fig. 2 where 5–40μg were used as indicated)
was separated by 10 % denaturing SDS-PAGE and subse-
quently transferred to nitrocellulose transfer membranes
(Whatman GmbH, Dassel, Germany). The primary polyclonal
antibody anti-GS (Sigma-Aldrich, G2781), recognizing GS
amino acids 357–373 with N-terminally added lysine accord-
ing to the manufacturer, was used at a dilution of 1:1000, and
the horseradish peroxidase (HRP)-conjugated secondary anti-
body anti-rabbit (Santa Cruz Biotechnology, Inc., Heidelberg,
Germany) was used at a dilution of 1:7500. Antibody against
β-actin (Santa Cruz Biotechnology) served as loading control.
Protein detection was done using ECL reagents (GE
Healthcare, Little Chalfont, UK) for chemiluminescent
labeling.
NAD+ measurement
NAD+ was measured using the EnzyChrom NAD+/NADH
Assay Kit (BioAssay Systems, Lausanne, Switzerland) ac-
cording to the manufacturer’s protocol. This assay is highly
specific for NAD+ with no interference from NADP+. To
make sure that samples were comparable, only samples with
350,000 to 550,000 cells in a fixed volume of 800 μl were
analyzed. In brief, cell-pellets were suspended in 100 μl of
NAD+ extraction buffer and lysed using a small douncer and
pestle. Cell extracts were heated at 60 °C for 5 min and then
20 μl assay buffer was added as well as 100 μl of the opposite
extraction buffer to neutralize the extracts. The samples were
briefly vortexed and spun down at 14,000 rpm for 5 min. Of
the supernatant, 40 μl was loaded with 80 μl working reagent
into a clear flat-bottom Greiner UV-Star 96-well plate (Sigma)
for NAD+ assay. The optical density was measured for time
Bzero^ and after 15-min incubation at 37 °C at 565 nm using
Infinite M200 plate-reader and the i-control6 software (both
from Tecan, Männedorf, Switzerland). NAD+ levels are given
per number of cells in the assay and presented as [nmol
NAD+/105 cells].
Statistics
Statistical analyses were done by one-way analysis of var-
iance (ANOVA) with the program GraphPad Prism 4
(GraphPad Software, San Diego, CA) to describe the dif-
ferences of NAD+ between controls’ and patient’s fibro-
blasts, leukocytes, and lymphocytes. Standard deviations
(SD) are shown in Table 1. Differences were considered
statistically significant if p-value was <0.05.
Results
Upregulated GS expression in patient cells and in absence
of glutamine
To determine the level of GS expression in cultured human
fibroblasts, we performed Western blotting (Fig. 2a). GS
Fig. 2 GS expression in cultured human fibroblasts of a control or a
patient with glutamine deficiency. a: Analysis of GS protein expression
in cultured fibroblasts with indicated amounts (5, 10, 20, 40 μg,
respectively) by Western-blot analysis. b: Effect of glutamine (Gln) and
nicotinamide (NAmide) on GS protein expression. Cells were cultured in
the presence (+) or absence (-) of glutamine (Gln) or nicotinamide
(NAmide) for 48 h. c: GS protein expression in control fibroblasts
cultured for 72 h in presence (+Gln) or absence (-Gln) of glutamine
(4 mM). GAPDH (a) or β-actin (b, c) served as a loading control
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protein was markedly upregulated in fibroblasts from the pa-
tient with glutamine deficiency as compared to human fibro-
blasts of a control. To study whether exogenous glutamine or
nicotinamide supplementation affects GS protein expression,
Western blotting was performed on homogenates from un-
treated cells or cells treated with glutamine or nicotinamide
for 48 h (Fig. 2b) or from control cells cultured with or without
glutamine for 72 h (Fig. 2c). Control cells cultured in the
presence of 10 mM (Fig. 2b) or 4 mM (Fig. 2c) glutamine
showed a slight decrease in GS expression compared to those
cultured in the absence of glutamine. In contrast, patient cells
did not show any change in the level of GS expression when
grown without glutamine (Fig. 2b). Likewise, nicotinamide
was without any effect on the expression levels of GS protein
relative to β-actin in fibroblasts from the control as well as the
patient (Fig. 2b).
Glutamine-, nicotinamide- or nicotinate- supplementation
normalize NAD+ levels in GS deficient fibroblasts
Since the reaction of NAD+ synthetase requires glutamine, we
first analyzed the NAD+ in vitro in fibroblasts and found a
significantly reduced NAD+ level (0.14±0.07 nmol NAD+/
105 cells) in a patient with glutamine deficiency compared to
a control (0.41±0.17 nmol NAD+/105 cells) (Fig. 3, Table 1).
To investigate the effect of glutamine and the NAD+ precur-
sors nicotinamide and nicotinate on NAD+ synthesis in GS
deficient cells, we added these agents to the culture medium
of fibroblasts from patient and controls. NAD+ in GS deficient
fibroblasts treated with glutamine or NAD+ precursors
nicotinamide or nicotinate was significantly increased
(0.36±0.19, 0.47±0.22 and 0.50±0.09 nmol NAD+/105
cells, respectively, all significantly above the untreated
cells, p<0.01) reaching levels comparable to controls
(0.46±0.21, 0.46±0.25, and 0.47±0.27 nmol NAD+/105
fibroblasts, respectively) (Fig. 3, Table 1). However, in
control cells, NAD+ levels remained unchanged under
any of the agents used (p>0.05). Combined treatment
with glutamine and nicotinamide had no synergistic ef-
fect on NAD+ levels in GS deficient cells. These results
indicate that GS deficiency results in partial NAD+ de-
pletion in fibroblasts, which can be rescued by supple-
mentation with glutamine and/or? the NAD precursors
nicotinamide and nicotinate.
Glutamine supplementation normalizes reduced NAD+
levels in GS deficient leukocytes
Next, we wanted to measure the NAD+ in vivo using leuko-
cytes isolated from the GS deficient patient and controls. In
patient’s leukocytes, NAD+ levels were close to zero (0.01±
0.01 nmol NAD+/105 leukocytes; results from nine indepen-
































































































































































































































































































































































































































































J Inherit Metab Dis (2015) 38:1075–1083 1079
found in fibroblasts (0.45±0.21 nmol NAD+/105 leukocytes)
(Fig. 4, Table 1). This suggests that GS deficiency results in
severe NAD+ depletion in leukocytes. To test whether gluta-
mine supplementation restores NAD+ levels in GS deficient
leukocytes, we investigated NAD+ levels in leukocytes of the
patient before and 4 weeks after treatment with L-glutamine
(details of this trial in (Häberle et al 2012)). During glutamine
supplementation of the patient, we observed that GS deficient
leukocytes showed a marked increase in NAD+ raising to 1.31
±0.40 nmol NAD+/105 leukocytes (controls 0.45±0.21 nmol
NAD+/105 leukocytes) (Fig. 4, Table 1). Taken together, these
results indicate that GS deficiency is associated with NAD+
depletion in leukocytes which can be rescued by glutamine
supplementation.
Reduced NAD+ levels in GS deficient peripheral blood
stem cells (PBSC) cannot be normalized to control levels
by supplementation with glutamine or nicotinamide
In order to extend our studies to other cell types, NAD+ level
was measured in vitro using PBSC isolated from blood sam-
ples from the GS deficient patient, the patient’s father, and
controls. Whereas NAD+ levels in the patient’s father (0.12±
0.01 nmol NAD+/105 PBSC) did not differ from controls
(0.13±0.03 nmol NAD+/105 PBSC), NAD+ levels in the GS
deficient PBSC (0.07±0.02 nmol NAD+/105 PBSC) were sig-
nificantly reduced when compared to PBSCs from the pa-
tient’s father and controls (Fig. 5, Table 1). This indicates that
GS deficiency is associated with NAD+ depletion in PBSC.
To investigate whether glutamine- and nicotinamide-
supplementation can ameliorate NAD+ depletion in GS defi-
cient PBSC, we treated PBSCs with L-glutamine and PBSCs
from the patient additionally with nicotinamide for 72 h. Sur-
prisingly, GS deficient PBSCs treated with L-glutamine or
nicotinamide showed no change in NAD+ levels (0.05±0.03
and 0.04±0.03 nmol NAD+/105 PBSC, respectively) (Fig. 5,
Table 1). Similarly, also PBSCs from patient’s father as well as
from controls treated with L-glutamine yielded unchanged
NAD+ levels. Taken together, these results indicate that GS
deficiency is associated with reduced NAD+ levels in PBSC
which cannot be normalized to control levels by glutamine or
nicotinamide supplementation.
Discussion
GS deficiency is an ultra-rare inborn error of metabolism with
not yet fully understood pathophysiology. The most obvious
cause for development of disease is the severe glutamine
Fig. 3 NAD+ levels in GS deficient and control fibroblasts. Control and
GS deficient cultured fibroblasts were treated with 10 mM glutamine
(Gln), 1 mM nicotinamide (NAmide), 1 mM nicotinate (NAte) or with
a combination of 10 mM glutamine and 1 mM nicotinamide for 48 h,
respectively. –Gln indicates cells were grown in standard culture medium
without glutamine for 48 h. NAD+ was measured from cell lysates using
EnzyChromNAD+/NADH assay and presented as nmol NAD+/105 cells.
Asterisks indicate that differences were significant with a p-value<0.001
Fig. 4 NAD+ levels in human leukocytes. Leukocytes from the GS
deficient patient (obtained in vivo) before and after treatment with
10 mM glutamine (+Gln) for 4 weeks and from controls were analyzed
for NAD+ levels. NAD+ was measured in cell lysates using EnzyChrom
NAD+/NADH assay and expressed in nmol NAD+/105 cells
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deficiency that was observed in all patients in different body
fluids and, in one patient, in brain tissue (Häberle et al 2005,
2011). However, since glutamine plays many important roles in
various cell-specific metabolic pathways in the human organ-
ism, it is expected that glutamine deficiency causes alterations
in the level and function of many co-enzymes and/or co-factors
which may aggravate the clinical phenotype. As such distur-
bances may be easily treatable and as this may have huge im-
pact on the patients’ welfare and function, it is important to
identify the secondary effects of glutamine deficiency. Here
we show that glutamine deficiency results in NAD+ depletion
in leukocytes, fibroblasts, and PBSC. Furthermore, we show
exogenous supplementation of glutamine, nicotinamide or
nicotinate rescues this biochemical phenotype in fibroblasts
and in leukocytes suggesting novel therapeutics for GS defi-
ciency, glutamine depletion, and/or NAD+/NADH pathologies.
We took advantage of the availability of cells and cell lines
from a patient with inherited GS deficiency due to the homo-
zygous missense mutation GLUL-p.Arg324Ser (Häberle et al
2011). The affected residue in this mutation, arginine-324, is
highly conserved and forms part of the ATP-binding site of the
enzyme (Krajewski et al 2008).Moreover, arginine-324 is part
of a loop, termed Bthe Glu327 flap^ consisting of residues
323–330, that guards the glutamate entrance to the active site
(Eisenberg et al 2000). We had previously performed a thera-
peutic trial in this patient by using enteral and parenteral glu-
tamine supplementation that was well tolerated and resulted in
an improved clinical status and partial correction of peripheral
and central glutamine deficiency (Häberle et al 2012).
Fibroblasts obtained from an aborted fetus with GS defi-
ciency previously demonstrated an upregulation of the GS
protein and a significant drop in the proliferation rate
(Vermeulen et al 2008). We confirm here in mature GS defi-
cient fibroblasts the upregulation of GS supporting the use of
cultured fibroblasts for experiments into the pathophysiology
of the disease. When cultured in the absence of glutamine,
patient cells showed a significant (p<0.001) NAD+ depletion.
However, this NAD+ depletion could be rescued by addition
of glutamine, nicotinamide or nicotinate to the culture medi-
um. The combined use of glutamine and nicotinamide did not
further increase the levels of NAD+. In control cells, NAD+
remained unchanged under any of the supplements. These
findings indicate that GS protein expression is up-regulated
on-demand for glutamine. Furthermore, they show that a de-
fective GS leads to partial NAD+ depletion in cultured fibro-
blasts that can be rescued by glutamine, the substrate of NAD+
synthetase, as well as by nicotinamide or nicotinate, precur-
sors of alternative NAD+ generation. We measured NAD+ in
this study as the biggest measurable differences under niacin
deficiency conditions, as we are exploring here with GS defi-
ciency, can be expected for measurements of NAD+, not
NADH, NADP, or NADPH (Tang et al 2008).
In addition to the in vitro investigations in fibroblasts, we
studied the situation in leukocytes in vivo. Different from
fibroblasts, NAD+ was almost absent in untreated leukocytes
from the GS deficient patient while levels in controls were in
the range seen in fibroblasts. NADasemay have contributed to
the initial result; however, as we found higher levels of NAD+
in control patients, we exclude this to be the primary cause.
The impact of glutamine for NAD+ levels was demonstrated
by marked increase in NAD+ in leukocytes after a 4 week
therapeutic trial with a final dose of glutamine of
1020 mg/kg/day (Häberle et al 2012). The increase even
outnumbered the levels in non-age-matched controls. Thus,
in agreement with the findings in fibroblasts, and representing
strong direct clinical experimentation data, the defective GS
leads to a severe NAD+ depletion in leukocytes that can be
rescued with glutamine.
Fig. 5 NAD+ levels in peripheral
blood stem cells (PBSC). PBSC
from the patient, the patient’s
father and controls were either left
untreated or treated with
glutamine (BGln^, 10 mM, 72 h)
and, in case of PBSC from the
patient with nicotinamide
(NAmide, 1 mM, 72 h) before
NAD+ was measured in cell
lysates using EnzyChrom NAD+/
NADH assay and expressed in
μM NAD+/105 cells. Asterisks
indicate that differences were
significant with a p-value<0.001
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To extend the studies further, we used immortalized PBSC
from the GS deficient patient and his father and measured
NAD+. Similar to fibroblasts but less pronounced than in leu-
kocytes, PBSC from the patient also showed a partial NAD+
deficiency with levels significantly (p<0.001) lower than in
the heterozygous father and in controls. In contrast to fibro-
blasts and leukocytes, levels of NAD+ did not increase upon
supplementation of glutamine or nicotinamide to the culture
medium. As there are families of glutamine transporters with
differential age- and cell-specific localization (Boulland et al
2003; Nissen-Meyer and Chaudhry 2013) these data suggest
that PBSCs may lack proper glutamine transporters at this
stage (as they are immature and undifferentiated) and thus
exogenous glutamine may not contribute to stimulation of
NAD+ synthesis. Similarly, transport of nicotinamide into
PBSC may have been hampered due to lack of the necessary
transport systems. Alternatively, NAD+ synthesis in PBSCs
may be regulated by different mechanisms. In either case,
the partial NAD+ deficiency in PBSC cannot be rescued by
exogenous supplementation of glutamine and/or nicotin-
amide. In conclusion, an inherited defect of GS leads, as a
result of the severe lack of glutamine, to NAD+ depletion. This
appears to be cell type-specific as NAD+ levels were signifi-
cantly reduced in fibroblasts and PBSC, while NAD+ levels in
leukocytes were almost negligible. This NAD+ depletion can
be rescued in vitro in fibroblasts and in vivo in leukocytes but
remains unchanged in immortalized PBSC further corroborat-
ing the cell-specific nature of glutamine- and nicotinamide
transport, metabolism and action.
The finding of NAD+ deficiency extends the pathophysio-
logical understanding of GS deficiency and underscores the
paramount importance of glutamine within the human metab-
olism. As a next step, it would be interesting to investigate
parts of the metabolome, such as the glycolysis pathway, the
citric acid cycle, anaerobic substrate level phosphorylation or
ATP synthesis, that all heavily depend on sufficient NAD+
availability. However, such studies would probably require a
suitable animal model. At present, our work already opens a
novel potential therapeutic option as treatment with nicotin-
amide, in addition to the supplementation of glutamine, it
could be considered in future patients with an inheritedGLUL
defect, possibly also in secondary GS deficiency, and in pa-
tients with NAD+ aberrations, as this may improve their brain
functions and their immunity (Bruzzone et al 2009; Tullius
et al 2014).
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